<DOC>
	<DOCNO>NCT01391117</DOCNO>
	<brief_summary>The purpose study determine genotype 1 Hepatitis C Virus ( HCV ) -infected participant , safety , tolerability , pharmacokinetics ( drug absorb body , distribute within body remove body time ) antiviral activity repeat dos TMC649128 give monotherapy give combination pegylated interferon + ribavirin . We assess pharmacokinetic/pharmacodynamic ( study medication affect body ) ( PK/PD ) relationship antiviral activity , active metabolite safety TMC649128 metabolites . We determine short term safety tolerability co-administration TMC649128 pegylated interferon + ribavirin multiple dose 14 day treatment-naive genotype 1 HCV-infected participant . We explore effect pegylated interferon + ribavirin pharmacokinetics TMC649128 multiple dose 14 day treatment-naive genotype 1 HCV-infected participant . We also assess preliminary way short term antiviral effect combination TMC649128 pegylated interferon + ribavirin 14-day dosing period treatment-naive genotype 1 HCV-infected participant .</brief_summary>
	<brief_title>TMC649128HPC1002 - Trial inGenotype 1 Hepatitis C Virus ( HCV ) - Infected Participants Determine Safety , Tolerability , Pharmacokinetics Antiviral Activity TMC649128 , Alone Combined With Pegylated Interferon + Ribavirin</brief_title>
	<detailed_description>TMC649128 nucleoside inhibitor ( NI ) hepatitis C virus ( HCV ) polymerase development treatment chronic hepatitis C infection . Treatment-naive genotype 1 HCV-infected participant participant never receive ( pegylated ) interferon ( [ Peg ] IFN ) , ribavirin ( RBV ) approve investigational treatment chronic HCV infection . Treatment-experienced genotype 1 HCV-infected participant define previous non-responder relapse subject previous treatment regimen ( IFN/RBV PegIFN/RBV ) , never receive HCV polymerase inhibitor HCV protease inhibitor treatment stop since least one year . This study Phase Ib , double-blind , randomize , placebo-controlled trial genotype 1 HCV-infected participant determine safety , tolerability , pharmacokinetics antiviral activity repeat dos TMC649128 give monotherapy give combination pegylated interferon + ribavirin . This trial consist 2 phase . In first phase TMC649128 give monotherapy 10 day different dos dose regimen . In second phase TMC649128 administer one select dose regimen combination PegIFN a-2a/RBV 14 day . ; All dosage TMC649128 placebo give orally fed condition . ; The monotherapy phase include 3 panel ( panel 1-3 ) combination therapy phase include 1 panel ( panel 4 ) . In panel 1 , subject randomly assign receive TMC649128 1000 mg q24h ( every 24h ) ( n=8 ) placebo ( n=2 ) q24h Days 1-10 . In panel 2 subject randomize Arm 1 Arm 2 within arm , subject randomly assign receive TMC649128 placebo follow : In arm 1 volunteer receive TMC649128 select dose ( n=8 ) placebo ( n=2 ) q12h Days 1-10 . In arm 2 volunteer receive TMC649128 select dose ( n=8 ) placebo ( n=2 ) q24h Days 1-10 . Panel 3 : TMC649128 select dose ( n=8 ) placebo ( n=2 ) q12h ( every 12h ) OR q24h Days 1-10 assignment determine randomization ; Panel 4 volunteer randomize Arm 1 Arm 2 . In panel 4 , arm 1 , 10 volunteer receive placebo ( q12h OR q24h , dose regimen match Arm 2 Panel 4 ) + PegIFN a-2a/RBV Days 1-14 . In Panel 4 , arm 2 , 10 volunteer receive TMC649128 select dose ( q12h OR q24h ) + PegIFN a-2a/RBV Days 1-14. ; The actual dose Panel 1 derive data obtain currently ongoing MC649128HPC1001 trial . The actual dose Panel 2 depend result Panel 1 ( total daily dose TMC649128 administer arm Panel 2 . The dose TMC649128 q24h regimen Arm 2 high q24h dose administer Panel 1 [ 1000 mg q24h ] ) . The actual dos dose regimen Panels 3 4 depend result Panels 1 2 ( data review meeting ) . Selection dose dose regimen Panels 2 , 3 4 also depend data obtain trial TMC649128HPC1001 . Dosing stay within exposure limit . The intended dos Panels 2 3 2000 mg 3000 mg q12h q24h , may adapt base previous clinical data . If need base outcome Panel 1 result , subject Panel 3 may eventually receive low dose Panel 1 . See detailed study description .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Documented chronic ( &gt; 6 month ) genotype 1a 1b Hepatitis C virus ( HCV ) infection Treatmentnaive volunteer , mean never receive ( Peg ) IFN , RBV approve investigational treatment chronic HCV infection ( Panels 1 , 2 , 3 4 ) OR volunteer document prior nonresponder relapser subject previous treatment regimen ( IFN/RBV pegylated IFN/RBV ) stop treatment least 6 month screen volunteer never receive HCV polymerase inhibitor HCV protease inhibitor treatment stop since least one year ( Panels 1 , 2 3 ) Volunteer HCV plasma RNA level &gt; 100,000 IU/mL screen Body Mass Index 18.0 35.0 kg/m2 Healthy base medical evaluation include medical history , physical examination , blood test , vital sign , electrocardiogram . Evidence liver cirrhosis Historical liver biopsy grade liver cirrhosis evidence presence oesophageal varix transient elastography ( Fibroscan ) result 14.6 kPa within 2 year prior screen Evidence decompensated liver disease define prior history current evidence ascites , hepatic encephalopathy , bleed oesophageal gastric varix Evidence renal dysfunction , document estimate creatinine clearance 70 mL/min Evidence cause significant liver disease addition hepatitis C , may include limited hepatitis B , drug alcoholrelated cirrhosis , autoimmune hepatitis , hemochromatosis , Wilson 's disease , nonalcoholic steatohepatitis , primary biliary cirrhosis Volunteer diagnose suspect hepatocellular carcinoma Volunteer receive receive treatment HCV 6 month screen Volunteer coinfected Human Immunodeficiency Virus1 ( HIV1 ) HIV2 , hepatitis A B virus infection , clinically active tuberculosis study screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>TMC649128</keyword>
	<keyword>HCV</keyword>
	<keyword>TMC649128HPC1002</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Hep C</keyword>
</DOC>